The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | A retrospective study of autoSCT outcomes in older adults with R/R classic Hodgkin lymphoma
Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, presents the findings of a multi-center international retrospective study that investigated the outcomes of autologous stem cell transplantation (autoSCT) in older adults with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). The study highlighted that while older adults do not have a significantly higher risk of relapse, they have a significantly higher risk of non-relapse mortality when compared to patients younger than 60, both in the long-term and in the immediate post-transplant period. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So in ASH 2024, we presented a multi-centre international retrospective study of outcomes of autologous stem cell transplant in patients with relapsed/refractory classical Hodgkin lymphoma, focusing on comparison between older adults and younger adults.
And what we found was that older adults had… the risk of relapse is not significantly different in older adults compared to younger adults, but non-relapse mortality is significantly higher at all post-transplant time points in older adults compared to younger adults...
So in ASH 2024, we presented a multi-centre international retrospective study of outcomes of autologous stem cell transplant in patients with relapsed/refractory classical Hodgkin lymphoma, focusing on comparison between older adults and younger adults.
And what we found was that older adults had… the risk of relapse is not significantly different in older adults compared to younger adults, but non-relapse mortality is significantly higher at all post-transplant time points in older adults compared to younger adults. So five-year non-relapse mortality is 10.9% in adults older than 60 years, which is significantly higher than younger adults that have non-relapse mortality of about 2.5% at five years.
Moreover, we also saw that in the immediate post-transplant period, so the first three months post-transplant, older adults had non-relapse mortality of 5% against a risk of relapse of 1%. So basically, adults older than 60 years are at higher risk of non-relapse mortality during the immediate post-transplant period. So non-relapse mortality is basically defined as death without preceding relapse.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Onclive: Honoraria; CurioScience: Honoraria; Merck: Research Funding; Beigene: Research Funding.
